Ethylene Glycol

Ethylene Glycol

SCHEMBL5162980

CCCCCC[C@@H](O)C/C=C\CCCCCCCC(=O)OCCOC(=O)CCCCCCC/C=C\C[C@H](O)CCCCCC.OCCO

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FFAR1 O14842 1/20 0.66
FFAR4 Q5NUL3 1/20 0.66
DGKA P23743 2/20 0.61
FAAH O00519 4/20 0.58
MGLL Q99685 1/20 0.56
EPHX2 P34913 1/20 0.55
PRKCE Q02156 1/20 0.52
PRKCQ Q04759 1/20 0.52
PRKCD Q05655 1/20 0.52
PRKCA P17252 1/20 0.52
LPAR1 Q92633 6/20 0.52
LPAR4 Q99677 3/20 0.52
LPAR2 Q9HBW0 3/20 0.52
LPAR3 Q9UBY5 3/20 0.52
ENPP2 Q13822 2/20 0.52
LPAR5 Q9H1C0 2/20 0.52
CES2 O00748 1/20 0.52
LPAR6 P43657 1/20 0.52
TRPV1 Q8NER1 1/20 0.52
NFKB1 P19838 1/20 0.50

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30775153 0.96 FFAR1 (0.71) FFAR1FFAR4DGKAFAAHMGLL
SCHEMBL26868705 0.96 FFAR1 (0.71) FFAR1FFAR4DGKAFAAHMGLL
SCHEMBL27513328 0.95 FFAR1 (0.66) FFAR1FFAR4DGKAFAAHMGLL
SCHEMBL142809 0.95 FFAR1 (0.66) FFAR1FFAR4DGKAFAAHMGLL
SCHEMBL16153880 0.95 FFAR1 (0.69) FFAR1FFAR4DGKAFAAHMGLL
SCHEMBL12836601 0.94 FFAR1 (0.64) FFAR1FFAR4DGKAFAAHMGLL
SCHEMBL3460445 0.94 FFAR1 (0.64) FFAR1FFAR4DGKAFAAHMGLL
SCHEMBL17451093 0.93 EPHX2 (0.65) FFAR1FFAR4DGKAFAAHMGLL
SCHEMBL2066896 0.93 EPHX2 (0.65) FFAR1FFAR4DGKAFAAHMGLL
SCHEMBL12842107 0.93 FFAR1 (0.63) FFAR1FFAR4DGKAFAAHMGLL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-116375396-B Self-cleaning rock slice real stone paint and preparation method thereof 天津德普威涂料有限公司 2025-01-24 CN claimed
CN-117777902-A Bio-based acrylate pressure-sensitive adhesive and preparation method thereof 厦门纬达树脂有限公司 2024-03-29 CN claimed
CN-116904019-A Modified glass fiber reinforced nylon composite material and preparation method thereof 福建师范大学泉港石化研究院 2023-10-20 CN claimed
CN-116375396-A Self-cleaning rock slice real stone paint and preparation method thereof 天津德普威涂料有限公司 2023-07-04 CN claimed
CN-105837893-A Cold-resistance halogen-free flame-retardant cable and preparation method thereof 苏州科茂电子材料科技有限公司 2016-08-10 CN claimed
CN-116348085-B Branched chain amino acid surfactants for personal care and cosmetic products 艾德凡斯化学公司 2025-05-16 CN disclosed
CN-119970540-A Branched chain amino acid surfactants for personal care and cosmetic products 艾德凡斯化学公司 2025-05-13 CN disclosed
CN-116375396-B Self-cleaning rock slice real stone paint and preparation method thereof 天津德普威涂料有限公司 2025-01-24 CN disclosed
CN-115515557-B Surfactants for personal care and cosmetic products 艾德凡斯化学公司 2024-10-29 CN disclosed
CN-117777902-A Bio-based acrylate pressure-sensitive adhesive and preparation method thereof 厦门纬达树脂有限公司 2024-03-29 CN disclosed
US-20240074973-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION CONTAINING EPI-NASTINE OR SALT THEREOF SANTEN PHARMACEUTICAL CO., LTD. (JP) 2024-03-07 US disclosed
US-20240058356-A1 PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL ADMINISTRATION CONTAINING EPI-NASTINE OR SALT THEREOF AND CONTAINING SULFUR-BASED ANTIOXIDANT SANTEN PHARMACEUTICAL CO., LTD. (JP) 2024-02-22 US disclosed
US-20070179211-A1 Energy-curable intaglio printing SUN CHEMICAL CORPORATIN (US) 2007-08-02 US disclosed
CN-1961052-A Energy curable intaglio printing inks SUN CHEMICAL CORP (US) 2007-05-09 CN disclosed
EP-1751241-A1 ENERGY-CURABLE INTAGLIO PRINTING INKS Sun Chemical Corporation (US) 2007-02-14 EP disclosed
WO-2005097927-A1 ENERGY-CURABLE INTAGLIO PRINTING INKS SUN CHEMICAL CORPORATION (US) 2005-10-20 WO disclosed
CN-1553796-A Compositions having enhanced deposition of topically active compounds on surfaces �йȲ��� 2004-12-08 CN disclosed
CN-1522150-A Agent containing fat (oil), which contains onion extract, the production and use thereof for caring, preventing or treating damaged skin tissue, especially scarred tissue Ī��ҩ��ɷ����Ϲ�˾ 2004-08-18 CN disclosed
CN-1481234-A Skin oils consisting of oil-soluble constitents Ī��ҩ��ɷ����Ϲ�˾ 2004-03-10 CN disclosed
CN-1481231-A Vesicle forming skin oil contg W/O-emulsifiers with hydrophilic-lipophilic balance of 2-6, method for prodn and use thereof Ī��ҩ��ɷ����Ϲ�˾ 2004-03-10 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240058356-A1 PHARMACEUTICAL COMPOSITION FOR TRANSDERMAL ADMINISTRATION CONTAINING EPI-NASTINE OR SALT THEREOF AND CONTAINING SULFUR-BASED ANTIOXIDANT TXNRD3, TXNRD1, SMOX FFAR1 2484/4885FFAR4 3004/4885DGKA 4235/4885
US-20240074973-A1 PHARMACEUTICAL COMPOSITION FOR TOPICAL ADMINISTRATION CONTAINING EPI-NASTINE OR SALT THEREOF ASAH2, ASAH1, ACER2 FFAR1 2834/4885FFAR4 3635/4885DGKA 2759/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.